Leonard E. Post

Dr. Leonard E. Post has over 30 years of experience in all stages of pharmaceutical and biotechnology company R&D from early drug discovery through clinical development and FDA approval. During his industry career, he has led numerous programs that have resulted in multiple clinical candidates across various therapeutic areas.

Dr. Post currently serves as Chief Scientific Officer at Vivace Therapeutics, Inc. Dr. Post is an Independent Director at Cold Genesys, Inc. since October 22, 2018. He served as the Chief Scientific Officer of BioMarin Pharmaceuticals Inc. since 2010 and served as its Vice President of Research. Dr. Post serves as a Scientific Advisor of Ambit Biosciences Corporation. He serves as Executive in Residence at Canaan Partners since 2010. He served as an Executive Advisor at Talu Ventures Pty Ltd. (also known as CM Capital Investments Pty Ltd.) since 2006 and also served as its Life Sciences Advisor. Dr. Post provides advice and expertise in drug and clinical development. He was the Founder and Chief Scientific Officer at LEAD Therapeutics, Inc. He served as the Senior Vice President of Research and Development at Onyx Pharmaceuticals, Inc. from July 2000 to December 31, 2005 and also served as its Consultant. He served as Consultant of BioVex, Inc. Dr. Post was responsible for the co-development (50:50 with Bayer) of Nexavar from IND through FDA approval for renal cell carcinoma at Onyx. Prior to joining Onyx Pharmaceuticals Inc. in 2000, he served in various management positions at the Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company, from 1991 to July 2000, including Vice President of Discovery Research from June 1997 to December 1999 and Vice President of Biologicals from January 2000 to July 2000. Prior to Warner-Lambert, Dr. Post spent 10 years at The Upjohn Company in various scientific and management positions including Director of Infectious Disease Research. Dr. Post served as the Chairman of Scientific Advisory Board of Pathway Therapeutics and Altiris Therapeutics, Inc. and serves as its Director and Member of Scientific Advisory Board. He serves as the Chairman and Director of the SAB for Altiris Pharmaceuticals. He serves as a Director of Orphagen Pharmaceuticals, Inc., and Fedora Pharmaceuticals Inc. He serves as a member of the board of directors at Vivace Therapeutics Inc. He served as a Non-Executive Director at Viralytics Limited since November 21, 2011 until June 20, 2018. He has been Member of DDR Advisory Committee at Sierra Oncology, Inc since August 15, 2017. He serves as a Member of Scientific Advisory Board at PNP Therapeutics, Inc. He served as a Director of LEAD Therapeutics, Inc. Dr. Post served as a Director of Praecis Pharmaceuticals Inc. since September 12, 2003. He served as Director of BioVex Group, Inc., and BioVex, Inc. since September 2007 and was also its consultant. Dr. Post served as a member of Drug Assessment Board of VIA Pharmaceuticals, Inc. From 1993 to June 2000, he served as Adjunct Professor in the Department of Microbiology and Immunology at the University of Michigan. He received a Bachelor of Science in Chemistry from the University of Michigan and a Ph.D. in Biochemistry from the University of Wisconsin, Madison after which he performed a Postdoctoral Fellowship in Virology at the University of Chicago.